BridgeBio Pharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| Cost of revenue | $21.0M | $3.9M | $2.4M | $3.4M | $2.7M |
| Selling, general & administrative | $531.2M | $288.9M | $150.6M | $143.2M | $192.2M |
| Research and development | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M |
| Interest expense | $53.1M | $91.0M | $81.3M | $80.4M | $46.8M |
| Pretax income | -$732.5M | -$542.2M | -$653.3M | -$484.7M | — |
| Income tax expense | $435,000 | $1.2M | $0 | $0 | — |
| Net income | -$732.9M | -$543.3M | -$653.3M | -$484.7M | -$586.5M |
| Balance Sheet | |||||
| Cash and equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M |
| Current assets | $797.7M | $720.7M | $477.6M | $548.9M | $888.9M |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B |
| Current liabilities | $288.0M | $154.4M | $143.8M | $121.4M | $135.1M |
| Total liabilities | $3.0B | $2.4B | $1.9B | $1.9B | $1.9B |
| Stockholders' equity | -$2.1B | -$1.5B | -$1.4B | -$1.3B | -$870.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M |
| Depreciation and amortization | $5.4M | $6.1M | $6.5M | $6.8M | $5.8M |
| Stock-based compensation | $133.0M | $95.8M | $108.7M | $91.6M | $99.5M |
| Capital expenditure | $1.1M | $933,000 | $1.3M | $4.8M | $13.2M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M |
| Share repurchases | $48.3M | $0 | $0 | $0 | $200.0M |
| Impairments | $0 | $271,000 | $0 | $12.7M | $0 |
Shares outstanding 195.9M · Free float 71.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.